Literature DB >> 10776805

SD3212, a new antiarrhythmic drug, raises atrial fibrillation threshold in isolated rabbit hearts.

R Matsuo1, T Shirayama, K Inoue, Y Matoba, H Imai, H Shiraishi, T Tatsumi, M Nakagawa.   

Abstract

SD3212 is a new antiarrhythmic drug which has class I, III, and IV effects. The purpose of this study was to elucidate the electrophysiological effects of this compound on a rabbit atrial fibrillation model, and to test a hypothesis that atrial fibrillation threshold is a quantitative indicator of atrial vulnerability. Whole hearts were excised from rabbits, and the aortas cannulated to perfuse the coronary arteries. Atrial fibrillation was induced with a burst stimulation of 50 Hz for 1 s while 3 microM acetylcholine (ACh) was perfused. When the right atrial appendage was paced at 200-ms intervals, SD3212 prolonged interatrial conduction time: control 30 +/- 1.2 ms, ACh 33 +/- 1.4 ms, ACh + SD 1 microM 37 +/- 2.4 ms, ACh + SD 3 microM 52 +/- 8.1 ms. The drug also prolonged the effective refractory period: control 80 +/-3.0 ms, ACh 48 +/- 3.8 ms, ACh + SD 1 microM 65 +/- 4.7 ms, ACh + SD 3 microM 98 +/- 15 ms. The rate of induction of atrial fibrillation by rapid pacing was 26% in Tyrode's solution, 85% in the presence of ACh, and 38% in the presence of ACh + SD 1 microM. The atrial fibrillation threshold decreased from 8.6 +/- 0.8mA (control) to 2.5 +/- 0.7 mA in the presence of ACh. It increased again to 7.8 +/- 1.0 mA in the presence of SD3212 (1 microM). SD3212 prolonged both the conduction time and refractory period. A reversed use-dependency was not prominent. These features caused antifibrillatory effects. Thus, the atrial fibrillation threshold seems to be a good quantitative indicator of atrial vulnerability.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10776805     DOI: 10.1007/bf02482296

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  25 in total

1.  Antiarrhythmic effects of a benzothiazine derivative (SD-3211) and its stereoisomer (SA3212) in anaesthetized rats and isolated perfused rat hearts compared with bepridil.

Authors:  M Fukuchi; T Uematsu; S Nagashima; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

2.  Effects of disopyramide on the atrial fibrillation threshold in the human atrium.

Authors:  K Ishibashi; D Inoue; R Sakai; M Inoue; T Shirayama; J Asayama; M Nakagawa
Journal:  Int J Cardiol       Date:  1995-11-24       Impact factor: 4.164

Review 3.  Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.

Authors:  B N Singh
Journal:  Am J Cardiol       Date:  1996-08-29       Impact factor: 2.778

4.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence.

Authors:  L M Hondeghem; D J Snyders
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

5.  Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital.

Authors:  W H Maisel; K M Kuntz; S C Reimold; T H Lee; E M Antman; P L Friedman; W G Stevenson
Journal:  Ann Intern Med       Date:  1997-08-15       Impact factor: 25.391

6.  Intra-atrial reentry as a mechanism for atrial flutter induced by acetylcholine and rapid pacing in the dog.

Authors:  M A Allessie; W J Lammers; I M Bonke; J Hollen
Journal:  Circulation       Date:  1984-07       Impact factor: 29.690

7.  Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide.

Authors:  M Inoue; D Inoue; K Ishibashi; R Sakai; I Omori; Y Yamahara; J Asayama; M Nakagawa
Journal:  Jpn Heart J       Date:  1993-05

8.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

9.  SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells.

Authors:  Y Hara; H Nakaya
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.

Authors:  M C Wijffels; C J Kirchhof; R Dorland; M A Allessie
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

View more
  1 in total

1.  Role of atrial fibrillation threshold evaluation on guiding treatment.

Authors:  Takeshi Shirayama
Journal:  Indian Pacing Electrophysiol J       Date:  2003-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.